Cures 2.0 Takes Off
The novel coronavirus may be propelling Cures 2.0 efforts to the forefront.
Prior Authorization’s Snowball Effect
Prior authorization was once a commonsense safeguard. But that is no longer the case.
New Paper Highlights Amyloidosis Patients’ Struggle for Access
It’s rare for a rare disease to have an FDA-approved treatment. Yet transthyretin amyloidosis, a complex disease caused by improper protein build-up, has three.
Long-term Care’s COVID Challenge
In early March, long-term care facilities such as nursing homes started to sound the alarm.
Spike in Hepatitis C Signals Treatment Access Barriers
Years after a cure became available for hepatitis C, infections are skyrocketing.
ICER Report Adds Insult to Injury for Cystic Fibrosis Patients
The threat of the coronavirus was bad enough.
Research Yields More Options for Parkinson’s Patients
A newly FDA-approved medication reflects how ongoing research continues to improve the treatment of Parkinson’s disease.
The Value of Ventilator Access
COVID-19 has made ventilator access a front-page issue. But for patients with chronic respiratory conditions, especially Medicare beneficiaries, the challenge is hardly a new one.
Shedding the IBS Stigma
I’ve never forgotten the story. It came from a man in a focus group I once conducted on irritable bowel syndrome.
The Hospital Bed Shortfall
Across the globe, patients infected with the novel coronavirus are arriving at their local hospitals for medical care. Will a hospital bed be available to them?
